Merck & Co. (MRK) — Company Research
Last Updated: 1 June 2026
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is one of the world's largest research-intensive biopharmaceutical companies. Its business is dominated by oncology — above all Keytruda, the best-selling prescription medicine in the world — alongside vaccines, cardiometabolic and respiratory drugs, hospital products and a sizeable Animal Health division. The central question facing the company is whether a deep pipeline and new launches such as Winrevair, Capvaxive and the subcutaneous Keytruda Qlex can offset the looming loss of exclusivity on intravenous Keytruda in 2028. This report reviews Merck's full-year 2025 results and first-quarter 2026 update using only company filings and press releases.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker | NYSE: MRK |
| Sector / Industry | Healthcare — Pharmaceuticals |
| Headquarters | Rahway, New Jersey, USA |
| Founded | 1891 |
| Employees | Approximately 75,000 |
| CEO / Leadership | Robert M. Davis (Chairman & Chief Executive Officer); Caroline Litchfield (Chief Financial Officer) |
| Market cap | ~$295 billion (late May 2026) |
| FY2025 revenue | $65.01 billion |
| FY2025 net income (GAAP) | $18.25 billion |
| FY2025 GAAP diluted EPS | $7.28 |
| FY2025 non-GAAP diluted EPS | $8.98 |
| Dividend (annualised) | $3.40 per share ($0.85 quarterly); ~2.9% yield |
| 52-week range | $75.40 – $125.14 |
2. Bull and Bear Case
Bull Case
- Keytruda scale and momentum: Keytruda generated $31.7 billion in 2025 (up 7%), driven by earlier-stage cancer indications, and remains the world's top-selling drug.
- Subcutaneous defence: The approval of subcutaneous Keytruda Qlex gives Merck a tool to migrate patients to a patent-protected formulation ahead of the 2028 intravenous loss of exclusivity.
- New launch engine: Winrevair (pulmonary arterial hypertension) reached $1.4 billion in its first full year, Capvaxive and Enflonsia are ramping, and Verona's Ohtuvayre adds a first-in-class COPD product.
- Animal Health and vaccines: Animal Health grew 8% to $6.4 billion, providing diversification, while the broader vaccine and cardiometabolic franchises add ballast.
- Low valuation and rising dividend: At roughly 16x trailing GAAP earnings with a ~2.9% dividend yield raised again for 2026, expectations embedded in the price are modest.
Bear Case
- Keytruda concentration: A single product is around half of company sales, and its core US patents expire in 2028, exposing Merck to a steep biosimilar-driven decline.
- Gardasil weakness: Gardasil/Gardasil 9 fell 39% to $5.2 billion in 2025, mainly on lower demand in China, removing a former growth engine.
- Acquisition-charge volatility: Merck includes acquired-research charges in non-GAAP EPS; the ~$3.65 per share Cidara charge pushed Q1 2026 into a reported loss and depresses 2026 guidance.
- Pipeline execution risk: Replacing Keytruda requires multiple pipeline assets — oncology ADCs, cardiometabolic and the obesity-adjacent programmes — to deliver on time.
- Policy and pricing: Medicare price negotiation, Part D redesign and international pricing pressure weigh on several franchises.
3. Business Segments
Merck reports in two segments — Pharmaceutical and Animal Health — with a small residual of other revenues. Full-year 2025 figures are shown below.
| Segment | % of revenue | What it is |
|---|---|---|
| Pharmaceutical | ~89.4% | Human health: oncology (Keytruda, Welireg, alliance products), vaccines (Gardasil, Capvaxive, Enflonsia), cardiometabolic and respiratory (Winrevair, Ohtuvayre), hospital, diabetes and virology. FY2025 sales $58.1bn. |
| Animal Health | ~9.8% | Livestock and companion-animal vaccines and medicines, including the Bravecto parasiticide line. FY2025 sales $6.4bn. |
| Other revenues | ~0.8% | Third-party manufacturing arrangements and miscellaneous corporate revenue. FY2025 sales $0.5bn. |
4. Business Model and Moat
How it makes money. Merck discovers, develops, manufactures and markets prescription medicines, vaccines and animal-health products worldwide. The bulk of profit comes from patent-protected human-health products, with oncology — led by Keytruda — the single largest contributor. Revenue is a mix of direct product sales and alliance/royalty arrangements with partners such as AstraZeneca (Lynparza, Koselugo), Eisai (Lenvima), Daiichi Sankyo and Bristol-Myers Squibb (Reblozyl royalties).
The moat. Merck's competitive advantage rests on intellectual property, a vast clinical-trial and regulatory machine, and entrenched physician relationships. Keytruda alone is supported by hundreds of trials and a layered patent estate spanning formulation, method-of-use and fixed-dose combinations that extends protection beyond the 2028 core composition-of-matter expiry. Scale in manufacturing biologics and vaccines, and a global commercial footprint, are difficult for new entrants to replicate.
Unit economics. Gross margins are high for a large-cap pharma, and the model is heavily reinvested: research and development absorbed $15.8 billion in 2025, reflecting both internal programmes and sizeable acquired-research charges from business-development deals.
5. Financial Health
Full-year figures are from Merck's audited results and quarterly press releases. Revenue is shown in US dollars. The 2023 result reflects a $4.02 per share charge for the Prometheus acquisition, and 2025 reflects continued business-development activity.
| Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE, $bn) |
|---|---|---|---|---|---|---|
| 2021 | 48,704 | — | 4.86 | 6.02 | 2.60 | 30.7 |
| 2022 | 59,283 | +21.7% | 5.71 | 7.48 | 2.76 | 28.7 |
| 2023 | 60,115 | +1.4% | 0.14 | 1.51 | 2.92 | 33.7 |
| 2024 | 64,168 | +6.7% | 6.74 | 7.65 | 3.08 | 34.5 |
| 2025 | 65,011 | +1.3% | 7.28 | 8.98 | 3.24 | ~40.0 |
For FY2025, cost of sales was $16.38bn, selling, general and administrative expense $10.73bn, and research and development $15.79bn; income before taxes was $21.07bn and GAAP net income attributable to Merck was $18.25bn. At 30 September 2025 long-term debt was $40.0bn (against $34.5bn at year-end 2024) and cash and cash equivalents were $18.2bn. Nine-month 2025 operating cash flow was $13.6bn with capital expenditure of $3.1bn; cash generation in 2025 was depressed by large business-development payments. The quarterly table shows the most recent periods first with the full-year 2025 total in bold.
| Quarter | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $16.29bn | $(1.28) | $(1.72) |
| Q4 2025 | $16.40bn | $2.04 | $1.19 |
| Q3 2025 | $17.28bn | $2.58 | $2.32 |
| Q2 2025 | $15.81bn | $2.13 | $1.76 |
| Q1 2025 | $15.53bn | $2.22 | $2.01 |
| FY 2025 | $65.01bn | $8.98 | $7.28 |
6. Valuation
Raw metrics, May 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$295bn |
| Trailing P/E (GAAP) | ~16.3x (price ~$118.51 / FY2025 GAAP EPS $7.28) |
| P/E (forward) | ~23x (price ~$118.51 / FY2026 non-GAAP EPS guidance midpoint ~$5.10; guidance absorbs a ~$3.65 per share one-time Cidara acquisition charge — excluding it, the forward multiple is ~13.5x) |
| P/S (TTM) | ~4.5x (market cap ~$295bn / FY2025 sales $65.01bn) |
| EV/EBITDA (TTM) | ~12.3x (EV ~$318bn / GAAP EBITDA ~$25.8bn; EBITDA ≈ pre-tax income $21.07bn + depreciation & amortisation ~$4.6bn) |
| P/FCF | ~21x (market cap ~$295bn / FCF ~$14bn; nine months to 30 Sep 2025 operating cash flow $13.6bn − capex $3.1bn = $10.5bn per Q3 2025 10-Q, annualised; 2025 cash flow depressed by large business-development payments) |
| Enterprise value | ~$318bn (market cap ~$295bn + total debt ~$41.4bn − cash ~$18.2bn per 30 Sep 2025 balance sheet) |
| 52-week high | $125.14 |
| 52-week low | $75.40 |
| Short interest (% of float) | ~1.1% (~27.5m shares short, May 2026) |
| Days to cover | ~2.55 |
7. Growth Drivers
Merck's near-term growth depends on defending and extending the Keytruda franchise while scaling a new wave of launches. The subcutaneous Keytruda Qlex formulation is central to bridging patients across the 2028 patent cliff, and a deep oncology pipeline of antibody-drug conjugates — including sacituzumab tirumotecan, ifinatamab deruxtecan and several Daiichi Sankyo-partnered assets — aims to broaden the cancer portfolio. Outside oncology, Winrevair is expanding in pulmonary arterial hypertension with new indications, the Verona acquisition adds Ohtuvayre in COPD, and Capvaxive and Enflonsia build out the vaccine business. The 2025 acquisitions of Verona Pharma (~$10bn) and Cidara Therapeutics (~$9.2bn, antiviral flu prevention) signal a strategy of buying late-stage, durable-growth assets to diversify away from Keytruda dependence. Animal Health provides a steadier, less patent-sensitive growth stream.
8. Peer Comparison
Merck competes across oncology, vaccines and broad pharmaceuticals against the other global large-cap drug makers. Market caps are approximate, as of June 2026.
| Peer | Market cap (Jun 2026) | Key 2025 metric |
|---|---|---|
| Eli Lilly (LLY) | >$1.0tn | Industry's most valuable company; incretin/obesity leader |
| Johnson & Johnson (JNJ) | ~$565bn | Diversified pharmaceuticals and medtech |
| AbbVie (ABBV) | ~$383bn | FY2025 net revenues $61.2bn; immunology $30.4bn |
| AstraZeneca (AZN) | ~$291bn | Oncology-led; competes with Keytruda in several tumour types |
9. Insider Activity
No insider transactions of note (open-market purchases or sales) were identified in Merck's recent Form 4 filings for the period reviewed; activity was limited to routine equity-plan grants and related awards. Chairman and Chief Executive Officer Robert M. Davis continues to lead the company, with Caroline Litchfield as Chief Financial Officer.
10. Key Risks
- Loss of exclusivity (Regulatory/IP): Intravenous Keytruda loses core US patent protection in 2028, placing more than $25bn of annual revenue in the path of biosimilars.
- Product concentration (Operational): Keytruda is around half of sales; any clinical, regulatory or competitive setback has an outsized effect.
- Gardasil and China (Macro/Commercial): Gardasil fell 39% in 2025 on weak China demand, illustrating exposure to single-market and geopolitical risk.
- Drug pricing and policy (Regulatory): Medicare negotiation, Part D redesign and international price controls reduce net pricing across the portfolio.
- Pipeline and integration (Operational): Offsetting the patent cliff depends on pipeline success and on integrating Verona, Cidara and other acquisitions.
- Earnings volatility (Financial): Including acquired-research charges in non-GAAP EPS makes reported earnings lumpy, as the Cidara charge showed in Q1 2026.
11. Recent Developments
- 30 Apr 2026 — Q1 2026 results. Sales rose 5% to $16.29bn with Keytruda up 8% to $8.03bn, but a ~$3.65 per share charge for the Cidara acquisition drove a GAAP loss of $(1.72) and non-GAAP loss of $(1.28); 2026 guidance was updated to sales of $65.8–67.0bn and non-GAAP EPS of $5.04–5.16.
- 06 Jan 2026 — Cidara acquisition completed. Merck completed its ~$9.2bn acquisition of Cidara Therapeutics ($221.50 per share), adding a late-stage antiviral for influenza prevention.
- 03 Feb 2026 — Q4 and full-year 2025 results. Full-year sales were $65.0bn (up 1%); non-GAAP EPS was $8.98 and GAAP EPS $7.28; Keytruda reached $31.7bn and Animal Health $6.4bn.
- 07 Oct 2025 — Verona Pharma acquisition completed. Merck completed its ~$10bn acquisition of Verona Pharma, adding Ohtuvayre (ensifentrine), a first-in-class COPD maintenance treatment.
12. Key Dates
- 15 Jun 2026 — record date for the third-quarter 2026 dividend of $0.85 per share
- 08 Jul 2026 — third-quarter 2026 dividend payment date
- 30 Jul 2026 — expected second-quarter 2026 earnings release (based on prior-year timing)
- 03 Feb 2027 — expected fourth-quarter and full-year 2026 results (based on prior-year timing)
Follow live pricing on ChartsView Live Charts, check the Economic Calendar, and join the discussion in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Merck is a research-driven pharmaceutical company that earns most of its profit from patent-protected medicines, above all the oncology blockbuster Keytruda, supplemented by vaccines, newer cardiometabolic and respiratory launches and an Animal Health division. Full-year 2025 sales were $65.0bn (up 1%) with non-GAAP EPS of $8.98, and after a Cidara-charge-driven loss in the first quarter management guides 2026 sales of $65.8–67.0bn. The defining driver is whether subcutaneous Keytruda Qlex and a deep oncology and launch pipeline can bridge the 2028 Keytruda patent cliff.
What would confirm or break it. Continued Keytruda growth, successful migration to the subcutaneous formulation and traction from Winrevair, Capvaxive and Ohtuvayre would confirm the transition. The thesis would be undermined by a faster-than-expected post-2028 biosimilar decline in Keytruda, further weakness in Gardasil, or pipeline setbacks that leave the company unable to offset the loss of exclusivity.
Watchpoints
- ConfirmsQ2 2026 earnings (59 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Keytruda scale and momentum:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Loss of exclusivity (Regulatory/IP):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 1 Jun 2026.